Subscribe

After Biologics Are Introduced, Hip and Knee Replacement Procedures Decline for Primary Diagnosis of Rheumatoid Arthritis

VBCR - May 2012, Volume 1, No 2 - Rheumatoid Arthritis

Chicago, IL—The number of total hip replacement (THR) and total knee replacement (TKR) surgeries has declined among patients with a primary diagnosis of rheumatoid arth­ritis (RA) since the introduction of biologic agents.

“This consistent and significant finding suggests that the availability of biologic agents, as well as other changes in the therapeutic approach to RA, may confer long-term benefits to both RA patients and healthcare systems,” concluded Neeta Tandon of Janssen Scientific Affairs, LLC, Hor­sham, PA, on a retrospective analysis of a large database of hospital inpatient stays, presented at the 2011 meeting of the American College of Rheumatology.

The researchers analyzed patient hospital discharge data between 1993 and 2008 using the Nationwide Inpatient Sample (NIS) of the Health­care Cost and Utilization Project. The NIS contains discharge data from more than 1000 US hospitals from 1988 to 2009, allowing analysis of trends over time.

To capture the trends for THR and TKR, data were compared between patients with RA before and after the introduction of infliximab (Remicade) in 1999, adalimumab (Humira) in 2002, and etanercept (Enbrel) in 1998, and to patients without a diagnosis of RA.

A coding algorithm was used to identify the 1.7 million patients having THR or TKR procedures, 58,036 of whom had a diagnosis of RA.

The number of annual THR surgeries more than doubled between 1993 and 2008—from 25,987 to 56,478—whereas, the number of annual TKR procedures more than tripled—from 38,136 to 125,881—during this period.

The number of THR and TKR surgeries increased for patients with RA as a secondary diagnosis and for patients with no indication of RA. During the same time, the number of THR and TKR procedures for patients with a primary diagnosis of RA was decreasing.
Patients with RA as a primary or a secondary diagnosis had a significant 28% decrease (P <.01) in the likelihood of RA being the primary reason for undergoing THR or a TKR procedure after the time that biologic agents were introduced.—WK

Related Items
Working in Cold Environment Increases Risk for RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Treatment with Methotrexate Alone Yields Similar Outcomes to Combination Therapy in Early RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Adalimumab Biosimilar Shown to Be Safe and Effective in Patients with RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Using Preference Phenotypes to Enhance Communication, Facilitate Treatment Decision-Making, and Personalize Care
Leslie Wyatt
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Web-Based Smartphone Application Useful for Monitoring Changes in RA Disease Activity
Sophie Granger
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Rheumatoid Arthritis
Upadacitinib Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Efficacy and Safety of Switching from Adalimumab to Sarilumab
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Cost per Effectively Treated Patient with Sarilumab for Active, Moderate-to-Severe RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology